BCM
TEVA icon

Bayesian Capital Management’s Teva Pharmaceuticals TEVA Stock Holding History

Bayesian Capital Management’s Portfolio TEVA Stock Details TEVA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-34,100
Closed -$554K – 1033
2024
Q2 		$554K Buy
+34,100
New +$525K 0.06% 344
2023
Q2 		– Sell
-39,300
Closed -$348K – 1061
2023
Q1 		$348K Buy
+39,300
New +$389K 0.04% 474
2022
Q3 		– Sell
-36,900
Closed -$277K – 1012
2022
Q2 		$277K Sell
36,900
-41,600
-53% -$362K 0.05% 507
2022
Q1 		$737K Buy
+78,500
New +$655K 0.11% 274
2021
Q2 		– Sell
-31,700
Closed -$366K – 638
2021
Q1 		$366K Sell
31,700
-92,000
-74% -$1.05M 0.08% 303
2020
Q4 		$1.19M Sell
123,700
-7,600
-6% -$72.8K 0.31% 81
2020
Q3 		$1.18M Buy
131,300
+70,300
+115% +$744K 0.29% 85
2020
Q2 		$752K Sell
61,000
-90,200
-60% -$1.02M 0.17% 174
2020
Q1 		$1.36M Buy
+151,200
New +$1.55M 0.29% 76
2018
Q4 		– Sell
-53,100
Closed -$1.14M – 783
2018
Q3 		$1.14M Buy
+53,100
New +$1.23M 0.19% 149
2017
Q2 		– Sell
-14,000
Closed -$449K – 591
2017
Q1 		$449K Buy
+14,000
New +$478K 0.21% 185
2016
Q4 		– Sell
-24,655
Closed -$1.13M – 703
2016
Q3 		$1.13M Buy
24,655
+10,455
+74% +$545K 0.74% 15
2016
Q2 		$713K Buy
+14,200
New +$756K 0.43% 58

Other funds holding TEVA

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
IAM
Ion Asset Management Herzliya, Israel $911M AUM 24.97% 1-Year Est. Return
CI
Clal Insurance Tel-Aviv, Israel $16.6B AUM 68.34% 1-Year Est. Return
MMH
Menora Mivtachim Holdings Ramat Gan, Israel $21.1B AUM 40.03% 1-Year Est. Return
LIM
Lingotto Investment Management London, United Kingdom $5.06B AUM 91.14% 1-Year Est. Return
MIFH
Migdal Insurance & Financial Holdings Petach Tikva, Israel $11.5B AUM 52.5% 1-Year Est. Return
PF
Phoenix Financial Givatayim, Israel $10.5B AUM 49.21% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return

Bayesian Capital Management's TEVA Position: Q3 2024 in Review

Bayesian Capital Management sold out of Teva Pharmaceuticals (TEVA) in Q3 2024, closing a stake of 34,100 shares — an estimated $554K sold.

Bayesian Capital Management first reported a position in TEVA in Q2 2016 and held it in 13 quarters. The position peaked at $1.36M in Q1 2020. 542 funds tracked by Wall St. Rank hold TEVA as of Q3 2024.

  • Bayesian Capital Management reported no remaining Teva Pharmaceuticals position as of Q3 2024 after selling out during the quarter.
  • Bayesian Capital Management sold 34,100 Teva Pharmaceuticals shares in Q3 2024, an estimated $554K.
  • Bayesian Capital Management first reported a position in Teva Pharmaceuticals in Q2 2016 and held it in 13 quarters.
  • Bayesian Capital Management's Teva Pharmaceuticals position peaked at $1.36M in Q1 2020.
  • 542 funds tracked by Wall St. Rank held Teva Pharmaceuticals as of Q3 2024.

Based on Bayesian Capital Management's 13F filing for Q3 2024, filed 14 Nov 2024.